AAAAAA

   
Results: 1-13 |
Results: 13
Farnesyl : protein transferase inhibitors as potential agents for the management of human prostate cancer
Authors: Sepp-Lorenzino, L Tjaden, G Moasser, MM Timaul, N Ma, Z Kohl, NE Gibbs, JB Oliff, A Rosen, N Scher, HI
Citation: L. Sepp-lorenzino et al., Farnesyl : protein transferase inhibitors as potential agents for the management of human prostate cancer, PROSTATE C, 4(1), 2001, pp. 33-43
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase
Authors: Dinsmore, CJ Bergman, JM Wei, DD Zartman, CB Davide, JP Greenberg, IB Liu, DM O'Neill, TJ Gibbs, JB Koblan, KS Kohl, NE Lobell, RB Chen, IW McLoughlin, DA Olah, TV Graham, SL Hartman, GD Williams, TM
Citation: Cj. Dinsmore et al., Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase, BIOORG MED, 11(4), 2001, pp. 537-540
Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency
Authors: Bell, IM Gallicchio, SN Abrams, M Beshore, DC Buser, CA Culberson, JC Davide, J Ellis-Hutchings, M Fernandes, C Gibbs, JB Graham, SL Hartman, GD Heimbrook, DC Homnick, CF Huff, JR Kassahun, K Koblan, KS Kohl, NE Lobell, RB Lynch, JJ Miller, PA Omer, CA Rodrigues, AD Walsh, ES Williams, TM
Citation: Im. Bell et al., Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency, J MED CHEM, 44(18), 2001, pp. 2933-2949
Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice
Authors: Gibbs, JB Graham, SL Hartman, GD Koblan, KS Kohl, NE Omer, C Pellicier, A Windle, J Oliff, A
Citation: Jb. Gibbs et al., Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice, CANC DRUG, 8, 2001, pp. 65-70
Mechanism-based target identification and drug discovery in cancer research
Authors: Gibbs, JB
Citation: Jb. Gibbs, Mechanism-based target identification and drug discovery in cancer research, SCIENCE, 287(5460), 2000, pp. 1969-1973
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS
Authors: Cohen-Jonathan, E Muschel, RJ McKenna, WG Evans, SM Cerniglia, G Mick, R Kusewitt, D Sebti, SM Hamilton, AD Oliff, A Kohl, N Gibbs, JB Bernhard, EJ
Citation: E. Cohen-jonathan et al., Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS, RADIAT RES, 154(2), 2000, pp. 125-132
Anticancer drug targets: growth factors and growth factor signaling
Authors: Gibbs, JB
Citation: Jb. Gibbs, Anticancer drug targets: growth factors and growth factor signaling, J CLIN INV, 105(1), 2000, pp. 9-13
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl : protein transferase inhibitor
Authors: Omer, CA Chen, ZX Diehl, RE Conner, MW Chen, HY Trumbauer, ME Gopal-Truter, S Seeburger, G Bhimnathwala, H Abrams, MT Davide, JP Ellis, MS Gibbs, JB Greenberg, I Hamilton, K Koblan, KS Kral, AM Liu, DM Lobell, RB Miller, PJ Mosser, SD O'Neill, TJ Rands, E Schaber, MD Senderak, ET Oliff, A Kohl, NE
Citation: Ca. Omer et al., Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl : protein transferase inhibitor, CANCER RES, 60(10), 2000, pp. 2680-2688
Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase
Authors: Dinsmore, CJ Williams, TM O'Neill, TJ Liu, DM Rands, E Culberson, JC Lobell, RB Koblan, KS Kohl, NE Gibbs, JB Oliff, AI Graham, SL Hartman, GD
Citation: Cj. Dinsmore et al., Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase, BIOORG MED, 9(23), 1999, pp. 3301-3306
Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase
Authors: Ciccarone, TM MacTough, SC Williams, TM Dinsmore, CJ O'Neill, TJ Shah, D Culberson, JC Koblan, KS Kohl, NE Gibbs, JB Oliff, AI Graham, SL Hartman, GD
Citation: Tm. Ciccarone et al., Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase, BIOORG MED, 9(14), 1999, pp. 1991-1996
N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity
Authors: Williams, TM Bergman, JM Brashear, K Breslin, MJ Dinsmore, CJ Hutchinson, JH MacTough, SC Stump, CA Wei, DD Zartman, CB Bogusky, MJ Culberson, JC Buser-Doepner, C Davide, J Greenberg, IB Hamilton, KA Koblan, KS Kohl, NE Liu, DM Lobell, RB Mosser, SD O'Neill, TJ Rands, E Schaber, MD Wilson, F Senderak, E Motzel, SL Gibbs, JB Graham, SL Heimbrook, DC Hartman, GD Oliff, AI Huff, JR
Citation: Tm. Williams et al., N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity, J MED CHEM, 42(19), 1999, pp. 3779-3784
Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase
Authors: Anthony, NJ Gomez, RP Schaber, MD Mosser, SD Hamilton, KA O'Neil, TJ Koblan, KS Graham, SL Hartman, GD Shah, D Rands, E Kohl, NE Gibbs, JB Oliff, AI
Citation: Nj. Anthony et al., Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase, J MED CHEM, 42(17), 1999, pp. 3356-3368
In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells
Authors: Mahgoub, N Taylor, BR Gratiot, M Kohl, NE Gibbs, JB Jacks, T Shannon, KM
Citation: N. Mahgoub et al., In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells, BLOOD, 94(7), 1999, pp. 2469-2476
Risultati: 1-13 |